David Lorenz, MS

Dave Lorenz has more than a decade of experience working on healthcare and life sciences matters. He specializes in statistical and economic analysis of issues involving healthcare providers, payers, PBMs, pharmacies, and pharmaceutical and medical device manufacturers involved in litigation, government investigations, and merger reviews. He collaborates with counsel and experts through all phases of litigation—including discovery, trial, and settlement negotiations. Dave also supports merging parties with advocacy submissions and Second Request compliance during merger reviews.

Dave has led small and large teams in a variety of contexts, including False Claims Act litigation and antitrust issues. His extensive experience leading these teams and supporting clients helps him anticipate client needs and guide teams to successfully meet those needs.

Dave enjoys leveraging data science tools and helped launch the firm’s Data Science Committee. Dave’s expertise in applying machine learning, data visualization, and big data processing techniques helps him derive meaningful insights to key questions. He takes pride in finding creative solutions to help clients make sense of data, such as developing interactive tools or producing data summaries they can rely on.

MS, Business Analytics, University of Virginia

BS, Economics, Schreyer Honors College, Penn State University

• On behalf of client’s proposed acquisition of a primary care medical group, supported the parties’ advocacy submissions to the Department of Justice (DOJ) and second request compliance. The DOJ closed its investigation, allowing the transaction to proceed.
• On behalf of client’s proposed acquisition of a long-term care pharmacy chain, supported the parties’ advocacy submissions to the Federal Trade Commission (FTC) and second request compliance. The transaction was cleared by the FTC.
• In Veeva Systems Inc. v. IQVIA Inc., supported testifying expert and counsel on issues of market definition, market power, theory of harm, and competitive effects concerning the monopolization of data and data management software for pharmaceutical companies.
• Led team supporting counsel with calculations and analysis related to Allergan’s multi-billion dollar global settlement with states, subdivisions, and special districts.

• In In re National Prescription Opiate Litigation, supported testifying experts and counsel with data analysis of marketing and prescribing data to evaluate causation and damages on behalf of a manufacturer defendant concerning allegations of inappropriate marketing of prescription opioids.

• In United States of America, ex rel. Michael Bawduniak v. Biogen IDEC Inc.,supported client with analysis of causation and damages. Relator alleged Biogen violated the FCA through kickbacks in the form of honoraria, meals, and other event-related remuneration to physicians.
• In New Jersey Primary Care Association, Inc. v. State of New Jersey Department of Human Services, et al., supported the expert in advising the plaintiff regarding the allocation of settlement proceeds among Federally Qualified Health Centers.
• In United States v. Novartis Pharmaceuticals Corp., supported Dr. Eric Gaier and counsel with analysis of marketing, prescribing, and claims data to assess causation and damages on behalf of Novartis in connection with alleged FCA violations associated with alleged kickbacks concerning Novartis’s promotional events for ten self-administered drugs indicated for hypertension or type 2 diabetes.